Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24

The award for the biggest M&A deal of the first quarter of 2024 goes to Gilead Sciences, which acquired CymaBay Therapeutics for $4.43 billion in February, according to a review of data from market intelligence platform S&P Capital IQ.